Corcept Therapeutics Q2 revenue estimates, raises 2026 outlook
CORT•Analyst coverage and valuation
The current average analyst rating on the shares is "buy", with 5 "strong buy" or "buy" ratings, no "hold" ratings, and 1 "sell" or "strong sell" rating.
The average consensus recommendation for the pharmaceuticals peer group is "buy". Wall Street’s median 12-month price target for Corcept Therapeutics Inc is $91.50, about 2.9% below its July 28 closing price of $94.19.
The stock recently traded at 51 times next-12-month earnings, versus a P/E of 52 three months ago.
Q2 revenue beats estimates, net income rises
Corcept Therapeutics said second-quarter revenue rose 32% year over year, beating analyst expectations. Net income for the quarter increased to $43.0 million from $35.1 million a year earlier.
Key details
| Metric | Beat/Miss | Actual | Consensus Estimate |
|---|---|---|---|
| Q2 Revenue | Beat | $256.15 million |
